Asset
MOTIXAFORTIDE
BioLineRx Ltd. American Depositary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02073019 | phase1 | completed | 2014-08-01 | 2015-07-01 | BioLineRx, Ltd. | A Phase I Study Evaluating Safety, Tolerability, PK and PD of BL-8040 for Stem Cell Mobilization in Healthy Volunteers |
| NCT03246529 | phase3 | active_not_recruiting | 2018-03-23 | 2020-12-22 | BioLineRx, Ltd. | A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM) |
| NCT02462252 | phase2 | completed | 2015-10-01 | 2020-11-01 | BioLineRx, Ltd. | Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome |
| NCT01838395 | phase2 | completed | 2013-04-01 | 2016-03-01 | BioLineRx, Ltd. | Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients |
| NCT03154827 | phase1_2 | terminated | 2018-01-08 | 2020-04-01 | BioLineRx, Ltd. | Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML) |
FDA applications (0)
This company has no applications containing this asset.